Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer
Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) announced that the first pediatric patient with microvillus inclusion disease (MVID) has entered the active treatment only, single-blind extension phase of its pivotal multicenter randomized double-blind crossover trial of liquid oral crofelemer as adjunctive therapy to parenteral support.
The extension will assess longer-term safety and efficacy to support planned NDA filing in mid-2027, subject to study completion and regulatory alignment. The trial spans the US, EU, and UAE, and crofelemer has orphan drug designation from FDA and EMA for MVID.
AI-generated analysis. Not financial advice.
Positive
- First pediatric MVID patient enters active-treatment-only extension phase of pivotal crofelemer trial
- Extension phase designed to generate longer-term safety and efficacy data in MVID
- Multicenter MVID trial running across US, EU, and UAE
- Pivotal MVID trial intended to support planned NDA filing in mid-2027
- Crofelemer holds orphan drug designation for MVID from FDA and EMA
- Additional MVID data from two expanded-access patients to be included in NDA package
Negative
- None.
News Market Reaction – JAGX
On the day this news was published, JAGX declined 9.32%, reflecting a notable negative market reaction. Argus tracked a peak move of +36.2% during that session. Argus tracked a trough of -8.7% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $201K from the company's valuation, bringing the market cap to $1.96M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
JAGX fell 5.61% while peers showed mixed moves: GRI up 5.97%, XRTX and AZTR modestly higher, QNRX and ONCO down. Momentum scanner shows ONCO sharply down 38.01% and PALI up 3.62%, underscoring stock‑specific, not sector‑wide, pressure.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | MVID trial extension | Positive | -8.0% | FDA feedback backing single-blind extension for pediatric MVID crofelemer trial. |
| Nov 20 | MVID protocol amend | Positive | -8.2% | Amended protocol to support possible expedited approval pathway for MVID. |
| Sep 24 | New orphan bid | Positive | +7.0% | Orphan Drug Designation application for crofelemer in cancer therapy-related diarrhea. |
| May 20 | First MVID randomization | Positive | +1.4% | First patient randomized in Phase 2 pediatric MVID crofelemer trial. |
| Dec 18 | Phase 2 MVID start | Positive | -8.5% | Initiation of Phase 2 crofelemer study for pediatric MVID with orphan status. |
Clinical trial and designation updates for crofelemer often see weak or negative next‑day moves despite largely positive clinical or regulatory content, with 3 divergences vs 2 alignments.
Over the past 18 months, Jaguar has steadily advanced crofelemer for Microvillus Inclusion Disease, from Phase 2 study initiation in Dec 2024 through first patient randomization in May 2025, protocol amendments for expedited pathways in Nov 2025, and FDA feedback supporting a single‑blind extension in Mar 2026. Price reactions to these clinical trial milestones averaged about -3.27% the next day, with several notable selloffs after positive news. Today’s continuation into an active‑treatment extension fits this ongoing development arc for the MVID program.
Historical Comparison
Clinical-trial headlines for Jaguar have averaged a -3.27% next-day move, with several selloffs after positive MVID milestones, so another negative reaction would not be unusual versus past patterns.
The MVID program has progressed from Phase 2 initiation and first patient dosing through protocol amendments and FDA-supported extension phases, culminating in patients now moving into an active-treatment extension to gather longer-term safety and efficacy data.
Regulatory & Risk Context
Jaguar has an effective S-3 shelf filed on 2025-10-03, with at least one utilization via a 424B3 prospectus on 2025-11-25. The shelf references prior private placements and warrants, including 492,612 warrants at an exercise price of $5.84, indicating established capacity to access capital as crofelemer programs advance.
Market Pulse Summary
The stock moved -9.3% in the session following this news. A negative reaction despite this extension milestone fits a pattern where clinical-trial news for Jaguar has produced average next-day moves of about -3.27%, with several prior MVID updates followed by declines. The stock already trades well below its $37.98 200-day MA and $219.55 52-week high, and faces ongoing Nasdaq compliance and financing considerations via its effective S-3 shelf. Continued trial progress and longer-term safety and efficacy data could be key to reshaping sentiment.
Key Terms
new drug application (nda) regulatory
randomized double-blind crossover medical
single-blind extension medical
parenteral support (ps) medical
total parenteral nutrition (tpn) medical
orphan drug designation regulatory
expanded access regulatory
open-label medical
AI-generated analysis. Not financial advice.
First MVID patient enters the active treatment only extension phase after completion of randomized double-blind crossover period to evaluate longer-term safety and efficacy with liquid oral crofelemer as adjunctive treatment for MVID, an ultrarare pediatric disease with a lethal natural history and no approved therapies, requiring lifelong parenteral support (PS)
SAN FRANCISCO, CA / ACCESS Newswire / May 19, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) announced that the first patient from the cohort of pediatric MVID patients in the pivotal MVID randomized double-blind crossover clinical trial has entered the active treatment only single-blind extension to evaluate the longer term safety and efficacy of crofelemer powder for oral solution as adjunctive treatment to parenteral support (PS) to support regulatory submissions for the drug to treat this serious unmet medical need. The trial is being conducted at multiple centers with appropriate regulatory approvals in the United States (US), European Union (EU), and United Arab Emirates (UAE).
MVID is an ultrarare congenital enteropathy that causes intestinal failure (IF) from early childhood. Patients with MVID require lifelong and life-sustaining PS, consisting of total parenteral nutrition (TPN) with or without supplemental intravenous fluids, to provide the life-sustaining nutrients, electrolytes, and fluids for survival. Most MVID patients require daily PS, sometimes for 20 hours or more per day. While crucial for growth and survival for these patients, PS is associated with significant comorbidities, such as liver and kidney toxicities, metabolic complications, infections, and neurodevelopmental delays. There are currently no approved drug treatments for MVID. Incidence of MVID is extremely rare with a lethal natural history. The company estimates that oral liquid crofelemer treatment is being used as adjunctive therapy with PS in up to
"In MVID, the therapeutic goal is to evaluate crofelemer's oral treatment to reduce the increased needs of PS to support growth, hydration, electrolytes, and nutritional requirements. This single-blind extension phase is an important clinical milestone for our pivotal randomized double-blind crossover clinical trial of crofelemer in the MVID trial to support the development and regulatory approval of the drug, intended to provide the longer-term safety and efficacy of crofelemer in MVID patients," said Dr. Pravin Chaturvedi, Chair of Scientific Advisory Board and Chief Scientific Officer of Napo Pharmaceuticals and Jaguar Health. "The decision to allow pediatric MVID patients to continue into the active treatment only single-blind extension phase after completion of the randomized double-blind crossover period is made by an independent data monitoring committee, which evaluates the safety data in a blinded setting."
"This continuation of this pivotal clinical trial of crofelemer for treatment of MVID, which has a lethal natural history without life-sustaining parenteral support, and the burden on children and families is a key milestone for our development and regulatory submission plans," added Lisa Conte, President and CEO of Jaguar. "Our team continues to evaluate expedited regulatory pathways to support the approval of crofelemer as a potential first-in-class adjunctive therapy, if approved, to decrease PS requirements and improve the quality of lives of these MVID pediatric patients."
As previously announced, Jaguar family company Napo plans to complete this pivotal, adequate and well-controlled clinical trial for the ultrarare pediatric MVID to support an NDA filing in mid-2027, subject to study completion and regulatory alignment. The Company will also include data from two additional MVID patients being evaluated under expanded access and open-label study protocols due to the ultrarare incidence and prevalence of MVID. Data from these two patients will be presented at the upcoming European Society of Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) annual meeting in June 2026. Jaguar has received orphan drug designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for crofelemer for MVID treatment.
Jaguar's MVID program is a part of the company's adult and pediatric intestinal failure (IF) development programs. In addition to MVID, the novel crofelemer powder for oral solution is also being evaluated in a blinded trial in adult patients with short bowel syndrome with IF (SBS-IF).
About Crofelemer Powder for Oral Solution
Crofelemer powder for oral solution is a novel investigational oral formulation for treating the rare and orphan gastrointestinal disorders that cause intestinal failure, including MVID and SBS-IF. Crofelemer is a novel, plant-based antisecretory agent that acts locally in the gastrointestinal tract and helps normalize fluid and electrolyte balance by modulating chloride ion secretion. The formulation remains investigational and is currently not approved by FDA or EMA for MVID and SBS-IF.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel, proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals Inc. (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire